Pfizer posted USD 28.4 billion in H1 2025 revenue, up 1% year-on-year, driven by 9% growth in oncology to USD 8.1 billion. ADCs from its Seagen acquisition contributed USD 1.5 billion, led by Nectin-4 ADC Padcev (enfortumab vedotin) at USD 967 million, +32%, and by CD30 ADC Adcetris (brentuximab vedotin) at USD 472 million. Breast cancer drug Ibrance (palbociclib) declined 7% to USD 2 billion amid competition, while prostate cancer therapy Xtandi (enzalutamide) expanded 12% to USD 1 billion.

Pfizer highlighted CD3/BCMA bispecific Elrexfio (elranatamab) as a potential myeloma standard, and PROTAC candidate vepdegestrant as its first oral protein degrader nearing approval. The company holds USD 13 billion for business development after licensing 3SBio's PD-1/VEGF bispecific SSGJ-707. CEO Albert Bourla emphasised pipeline advancements including ADC combinations to sustain long-term growth.

According to PharmCube's NextBiopharm® database, Seagen's products have generated Pfizer around USD 5 billion so far, only a fraction of the USD 43 billion 2023 valuation of the deal. Click here to request a free trial for NextBiopharm®.